Triventures

Triventures is a Tel Aviv health-tech fund built specifically around the convergence of data, AI, and clinical medicine, with strategic partnerships into tier-one global healthcare providers that give portfolio companies unusual access to real-world validation environments. For physician founders, those provider partnerships are a meaningful operational advantage, particularly in a market where access to clinical data and pilot sites often determines which companies survive Series A.

The thesis is concentrated on software-driven healthcare: digital health platforms, AI in healthcare, and medical devices where data and software are the moat. Triventures looks for companies that can use clinical partnerships to accelerate evidence generation and commercial deployment, which means founders should arrive with a clear plan for how they would use a hospital relationship rather than treating it as a generic asset. The fund does not publish a healthcare-specific portfolio carve-out, but the operating model is built around the convergence thesis.

Check sizes sit in the 1 million to 5 million dollar range at entry, with the fund operating across seed, Series A, and Series B. Triventures can lead or co-lead seed rounds and will follow on through Series B when a company performs. Geography is Israel-anchored but globally focused, with the strategic-provider partnerships providing United States and European access. The fund expects portfolio companies to be global from a relatively early stage.

The team is small and clinically literate, with partners who understand both the venture process and the operational realities of healthcare-provider relationships. Diligence is substantive and the fund engages hands-on with portfolio companies on commercial and clinical strategy.

Approach Triventures when you are an Israeli healthtech founder with a software-or-data-driven product, early clinical validation, and a clear thesis on how strategic provider partnerships would accelerate your business. Pure consumer-wellness plays without a provider angle will be a worse fit, as will deep biotech or therapeutics. Warm introductions from Israeli healthtech operators, hospital executives, or other healthtech-specialist VCs are the most reliable path in. Time the conversation when you have a working product, early pilot or commercial traction, and a real round forming. Pre-seed founders with only a deck will be a worse fit; the fund engages most productively once there is something to validate. Triventures is built for founders who want a clinically engaged partner rather than a hands-off check.